Core Laboratories N.V. (CLB) — Fair Value Analysis

Base-case fair value (P50): $10.98 · Current price: $11.61 · Verdict: Fairly Valued

The Verdict on CLB

CORE LABORATORIES INC (CLB) currently trades at $11.61, with Monte Carlo simulations indicating a median fair value (P50) of $10.98. This suggests an -5.4% difference against the current price, leading to our verdict that CLB is Fairly Valued. While some minor fluctuation is expected, the proximity of the current market price to the statistically derived median fair value suggests the market is largely reflecting its intrinsic worth based on thousands of forward-looking scenarios.

How CLB stacks up against peers

Our analysis tiers CLB's overall quality as "average" when assessing its operational and financial health compared to its sector. This average quality tier suggests that while CLB is a stable operator, it doesn't consistently exhibit sector-leading strengths or significant weaknesses that would materially push its valuation far from the median. The Monte Carlo simulation inherently accounts for these fundamental characteristics, anchoring the fair value assessment around $10.98 even as it explores a wide range of future possibilities. The current market price of $11.61 aligns well with this average operational profile.

What this means for investors

Given CLB's Fairly Valued status, with $11.61 sitting near $10.98 and an -5.4% spread, investors should interpret this as a stock trading largely in line with its fundamental valuation. Monte Carlo simulations provide a robust, probabilistic view, revealing a balanced risk-reward profile without significant immediate mispricing. While a downside scenario or a bull case can always emerge, the current data suggests CLB is reasonably priced. For a deeper understanding of these scenarios, FairCurve users can explore the full bear-case (P10) and bull-case (P90) distributions. Sign up for FairCurve to see the full bear/bull distribution and track CLB's fair value as new fundamentals are released.